Citadel Advisors
MRNA icon

Citadel Advisors’s Moderna MRNA Stock Holding History

Citadel Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151M Sell
2,973,600
-1,485,600
-33% -$69.3M 0.02% 591
2025
Q4 		$132M Sell
4,459,200
-1,565,700
-26% -$42.5M 0.02% 695
2025
Q3 		$156M Buy
6,024,900
+1,827,500
+44% +$51M 0.02% 596
2025
Q2 		$116M Sell
4,197,400
-697,900
-14% -$18.4M 0.02% 680
2025
Q1 		$139M Buy
4,895,300
+1,482,200
+43% +$52.6M 0.03% 517
2024
Q4 		$142M Buy
3,413,100
+896,300
+36% +$42.8M 0.02% 548
2024
Q3 		$168M Buy
2,516,800
+702,300
+39% +$64.5M 0.03% 432
2024
Q2 		$215M Sell
1,814,500
-331,700
-15% -$42M 0.04% 324
2024
Q1 		$229M Sell
2,146,200
-192,900
-8% -$19.4M 0.04% 322
2023
Q4 		$233M Sell
2,339,100
-351,200
-13% -$29.5M 0.05% 296
2023
Q3 		$278M Buy
2,690,300
+832,700
+45% +$92.9M 0.06% 217
2023
Q2 		$226M Sell
1,857,600
-47,200
-2% -$6.3M 0.05% 277
2023
Q1 		$293M Sell
1,904,800
-2,392,200
-56% -$395M 0.06% 203
2022
Q4 		$772M Buy
4,297,000
+2,241,900
+109% +$367M 0.18% 60
2022
Q3 		$243M Buy
2,055,100
+237,800
+13% +$36.1M 0.06% 245
2022
Q2 		$260M Sell
1,817,300
-1,465,600
-45% -$209M 0.07% 207
2022
Q1 		$566M Buy
3,282,900
+217,600
+7% +$36.6M 0.12% 91
2021
Q4 		$779M Buy
3,065,300
+196,000
+7% +$57.3M 0.16% 59
2021
Q3 		$1.1B Buy
2,869,300
+251,900
+10% +$92.9M 0.23% 42
2021
Q2 		$615M Sell
2,617,400
-709,600
-21% -$127M 0.14% 72
2021
Q1 		$436M Buy
3,327,000
+954,900
+40% +$138M 0.11% 105
2020
Q4 		$248M Buy
2,372,100
+731,200
+45% +$74M 0.06% 191
2020
Q3 		$116M Buy
1,640,900
+876,300
+115% +$61.1M 0.03% 388
2020
Q2 		$49.1M Buy
764,600
+534,200
+232% +$29.3M 0.02% 814
2020
Q1 		$6.9M Buy
230,400
+198,800
+629% +$4.57M ﹤0.01% 2301
2019
Q4 		$618K Sell
31,600
-45,400
-59% -$805K ﹤0.01% 6463
2019
Q3 		$1.23M Buy
77,000
+11,000
+17% +$162K ﹤0.01% 5239
2019
Q2 		$966K Buy
66,000
+31,400
+91% +$674K ﹤0.01% 5755
2019
Q1 		$704K Buy
+34,600
New +$642K ﹤0.01% 6207

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's MRNA Position: Q1 2026 in Review

Citadel Advisors reduced its Moderna (MRNA) stake by 15% in Q1 2026, selling an estimated $4.17M and leaving 489,770 shares worth $24.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $168M in Q2 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Citadel Advisors held 489,770 shares of Moderna worth $24.9M as of Q1 2026.
  • Citadel Advisors sold 89,360 Moderna shares in Q1 2026, an estimated $4.17M.
  • Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2063 holding.
  • Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.